Bristol Myers Squibb (BMS) is deploying its second NVIDIA DGX SuperPOD, featuring eight DGX Vera Rubin NVL72 systems, to double its AI compute capacity in life sciences. This new system offers up to 10x the performance per megawatt of its predecessor and will provide researchers with a unified AI platform, including NVIDIA BioNeMo Agent Toolkit, for drug discovery.
NVIDIA's next-gen Vera Rubin platform is securing significant enterprise adoption, validating its performance claims and locking in compute demand from critical sectors like life sciences.